Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

30 Mar 2020

Abstract excerpt

Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and promote the death of breast cancer cells lacking mutations in BRCA1/2. Here, we examined the inhibitory potency of 13 different PARPi in 12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32235451
DOI: 10.3390/jcm9040940

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA StatusPMID 32235451Read ↗

An Overview of PARP Inhibitors for the Treatment of Breast CancerSemantic proximity Read ↗

The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literatureSemantic proximity Read ↗

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesSemantic proximity Read ↗

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.Semantic proximity Read ↗

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) InhibitorsSemantic proximity Read ↗

Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: TalazoparibSemantic proximity Read ↗

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity Read ↗

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Semantic proximity Read ↗

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read ↗

PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer TreatmentSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?Semantic proximity Read ↗

Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: An updated systematic review and meta-analysis of randomized controlled trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.